Frontlight ResearchEarly access
Taking people in BelgiumPhase 3
Long-term safety follow-up of patients treated with Galapagos CAR T-cell therapies
Checks long-term safety of CAR T-cell treatment in adults with blood cancers.
Key facts
- Who runs it
- Lakefront Biotherapeutics
- Where
- Edegem, Leuven, Liège, Roeselare, and Sint-Lambrechts-Woluwe, BelgiumSee the 5 sitesAlso in 3 other countries, 6 sites
- Trial code
- Registry title
- A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 309 people, planned
- Started
- 9 Sept 2024
- Expected to end
- 20 Jul 2039
- Type of study
- Interventional
- Record updated
- 11 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who were treated with a Galapagos (GLPG) CAR T-cell therapy in a clinical trial or Managed Access Program. It follows their long-term safety.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Earlier treatment
- Must have been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program.
Main reasons for not taking part
- The record lists no exclusion criteria.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Subject must sign and date the ICF as approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any study-related procedures
- Subjects has been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program
Who cannot take part
- There are no exclusion criteria for this study
Where in Belgium
Also in 3 other countries, 6 sites
- Antwerp University HospitalEdegem, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
- Centre Hospitalier Universitaire de LiègeLiège, BelgiumTaking people
- Algemeen Ziekenhuis DeltaRoeselare, BelgiumTaking people
- Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumTaking people
About the trial
What the trial wants to find out
To evaluate the long-term safety of GLPG CAR T cell products for up to 15 years post CAR T cell product infusion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies
- Plain-language title
- Long-term safety follow-up of patients treated with Galapagos CAR T-cell therapiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 September 2026